GlassScriptPhysician profile
Shenelle Wilson
NPI 1215283775
$113,411.65
in general payments reported to CMS, 2019-2025
28 companies · $47K in 2025
The $47K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,704 · 2020: $382 · 2021: $3,498 · 2022: $17K · 2023: $23K · 2024: $21K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Consulting Fee: $16K · Travel and Lodging: $12K · Food and Beverage: $3,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,540.60 |
| Consulting Fee | $15,920.00 |
| Travel and Lodging | $11,873.99 |
| Food and Beverage | $3,724.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $85,901.55 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $12,431.42 | 2021-2022 | |
| Coloplast Corp | $5,143.56 | 2019-2025 | Titan, Porges Coloplast, Altis |
| Valencia Technologies Corporation | $2,244.50 | 2022-2024 | Ecoin Device Kit |
| Boston Scientific Corporation | $2,195.36 | 2020-2025 | General - Erectile Dysfunction, Bulkamid, Advantage System |
| Axonics, INC. | $1,784.50 | 2020-2023 | Bulkamid |
| Medtronic, INC. | $1,261.63 | 2021-2025 | Interstim |
| Procept Biorobotics Corporation | $1,228.39 | 2023 | Aquabeam Robotic System |
| Cosette Pharmaceuticals INC. | $212.39 | 2024-2025 | Vyleesi |
| Laborie Medical Technologies Corp. | $185.29 | 2021-2025 | |
| Thd America, INC. | $167.90 | 2024 | |
| Astellas Pharma US INC | $105.54 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $91.19 | 2021-2022 | |
| Abbvie INC. | $56.87 | 2023-2024 | Botox |
| Angiodynamics, INC. | $54.97 | 2023 | Nanoknife |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $52.94 | 2022 | |
| Dornier Medtech America, INC | $51.70 | 2022 | |
| Allergan, INC. | $49.83 | 2022 | |
| Olympus America INC. | $43.17 | 2022-2024 | Itind System |
| Teleflex LLC | $31.49 | 2021 | |
| Rochester Medical Corporation | $26.71 | 2020 | |
| Myovant Sciences INC. | $21.51 | 2021 | |
| Endo USA, INC. | $18.06 | 2025 | Xiaflex, Aveed |
| Alnylam Pharmaceuticals INC. | $16.96 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.40 | 2021 | |
| Astellas Pharma Global Development | $15.00 | 2019 | |
| Travere Therapeutics, INC. | $3.82 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shenelle Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.